Navigation Links
Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus
Date:3/10/2009

HONG KONG, March 10 /PRNewswire-Asia/ -- Obio Pharmaceutical Holdings Ltd ("Obio"/ "the Company") announced the discovery of a new indication of a drug, TG21, against main strains of influenza virus (including avian and human influenza strains) such as H3N2 and H5N1. The process leading to clinical trials for TG21 has already commenced.

"Obio has and will continue to engage prestigious institutions in USA and China to conduct various researches, all of which have endorsed that TG21 has antiviral effect towards a wide spectrum of influenza virus. Testing on chick embryo, chick, and mice are conducted. The finding indicated TG21 can increase the survival rate and decrease the amount of virus of animals challenged by Avian Influenza virus H5N1. TG21 possesses a complete safety profile as the active ingredient of the compound is already a drug approved by the US Food and Drug Administration (FDA) and EU European Medicines Agency (EMA) for chronic use to treat a rare disease, and there are no serious side effects recorded." Dr. Bill Piu Chan said.

After years of study to prove the efficacy of TG21 in tackling influenza virus, scientists are still investigating the basic mechanism of TG21. However, it is certain that TG21 works on a different mechanism to that of both Tamiflu(TM) and Relenza(TM). The two readily available drugs are Neuraminidase Inhibitors that prevent the virus from spreading to other cells. Both of them have similar antiviral mechanisms towards influenza virus.

Delivered in pills, Tamiflu(TM) and the inhaler drug-Relenza(TM) are the only drugs suggested by US FDA and World Health Organization for treating and preventing avian flu infection at present. However, cases of resistance to the mainstream medical intervention-Tamiflu (TM) are on the rise as shown in reports by U.S. Center of Disease Control and Prevention and the EU-Supported Network for Vigilance against Viral Resistan
'/>"/>

SOURCE Obio Pharmaceutical Holdings Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
2. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
3. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
4. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
5. Merz Aesthetics, a Division of Merz Pharmaceuticals USA, Introduces a Universal Language of Aging for Use in Education, Research and Practice
6. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
7. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
10. Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
11. Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Volunteers from the Church ... drug abuse this summer with massive distribution of ... can find these volunteers on Strøget, the famous Copenhagen ... for its shopping and its ambiance, some quarter of ... typical summer day. , These activities are part ...
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... from uncontrollable brain bleeding has filed a Xarelto lawsuit ... by the blood thinner, Bernstein Liebhard LLP reports. According ... Court for the District of Vermont on July 25th, ... days when he suffered an irreversible brain bleed that ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... July 30, 2014 DRE Medical — ... announce the launch of its Medical Trade Shows ... for medical professionals and equipment vendors. , The calendar ... conventions in the United States and around the world. ... and that number is always growing. , Information listed ...
(Date:7/30/2014)... Georgia (PRWEB) July 30, 2014 The ... and Technology Alliance of TAG (B&TA), today issued its ... TAG Excalibur Awards. , Interested companies have until August ... after which, Semi-Finalists will be selected by the Excalibur ... required to meet with the judges for interviewing process. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3
... Agency for Healthcare Research and Quality has reported that more ... treat burn victims is billed to Medicare or Medicaid, government ... ,According to statistics, the average charge is $59,600 ... the average charge for burn victims with private insurance ...
... is here to stay has made it necessary for health ... scenario Rush University Medical Center has pioneered the use of ... to respond quickly to infants in distress from any chemical ... of Public Health and the Health Resources and Services Administration ...
... race of a person was used as a basis to ... according to report published in the Journal of the American ... risky than that of their Indian and White compatriots, where ... policy is said to have been implemented by the South ...
... may be the reason for neural tube defects outbreak in ... ,The study published in the on line journal Environmental ... been infected by fungal toxins might give rise to neural ... pregnancy. ,Talking about “Neural tube defects” these ...
... error can make even a stone cry. Lis Noris, ... given radiation therapy, for brain tumor at Beatson Oncology ... to a rude shock of being the unfortunate recipient ... fatal. ,Doctors have admitted to human error, while ...
... a disease buster might be now challenged. ,A University of ... and grains had no reduced risk of two types of cancer ... ,The drawback of the study as perceived by some experts is ... of unhealthy food than the healthy foods., ,As said by ...
Cached Medicine News:Health News:Fungal toxins infected corn the reason for congenital defects 2Health News:Human Error: Teenager’s Renewed Zest for Life Nose-Dive 2Health News:Fat isn't all that bad: Reduction no predecessor of reduced disease 2
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes....
The Perfect Vac Quad Manifold allows one to four 96-well plates to be processed simultaneously. A single plate may be processed in 30 minutes; four plates are processed in 45 minutes....
... and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous acclaim with over ... ... ... ...
... The TurboVap Concentration Workstations from Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down ... use around the world today. ... ... ...
Medicine Products: